Mei Yanliang, Yang Jing, Yuan Yanpeng, Liu Yutao, Liu Xiaojing, Li Mingli, Fan Shiheng, Li Lanjun, Jiang Chenyang, Xu Yuming
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
National Health Commission Key Laboratory of Cerebrovascular Disease, Zhengzhou University, Zhengzhou, China.
Front Neurol. 2021 Oct 5;12:709553. doi: 10.3389/fneur.2021.709553. eCollection 2021.
Both specific and innate immune responses play important roles in autoimmune encephalitis (AE). We aimed to explore the predictive value of the systemic inflammation index (SII) at admission as a peripheral biomarker of treatment response of AE. A total of 146 patients diagnosed with AE in the First Affiliated Hospital of Zhengzhou University from January 1, 2018 to September 22, 2020 were retrospectively and consecutively analyzed as per the inclusion criteria and divided into two groups according to their response to immunotherapy after 30 days. The predictive value of the SII as a peripheral biomarker for AE treatment response was calculated using the receiver operating characteristic curve analysis, which showed that the best SII cut-off value for predicting poor response to AE treatment was 863.3; the area under the curve was 0.75, with 83.0% sensitivity and 72.0% specificity. The risk factors for poor response to AE treatment were analyzed; univariable analysis showed that the rate of decreased level of consciousness, rate of cognitive or mental behavior abnormality, cerebrospinal fluid pressure, blood neutrophils, platelets, time until treatment initiation, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and SII were significantly higher in patients with poor response to AE immunotherapy after 30 days than in patients with good response. Meanwhile, the blood lymphocyte counts and Glasgow Coma Scale (GCS) scores in patients with poor response were significantly lower than those in patients with good response (all < 0.05), and multivariable binary logistic regression with backward stepwise method showed that decreased levels of consciousness, time until treatment initiation and SII were associated with poor response to immunotherapy. Moreover, the SII ≤ 863.3 group had lower rates of decreased consciousness levels, admission to the intensive care unit, and mechanical ventilation; lower cerebrospinal fluid pressure, blood neutrophil count, and platelet count; and higher blood lymphocyte count and GCS scores. The SII was associated with worsened disease severity and poor response to treatment after 30 days of the initially diagnosed AE, and patients with an SII > 863.3 were more likely to have poor response to immunotherapy.
特异性免疫反应和先天性免疫反应在自身免疫性脑炎(AE)中均发挥重要作用。我们旨在探讨入院时全身炎症指数(SII)作为AE治疗反应外周生物标志物的预测价值。回顾性连续分析了2018年1月1日至2020年9月22日在郑州大学第一附属医院确诊为AE的146例患者,根据纳入标准,按照30天后对免疫治疗的反应将其分为两组。采用受试者工作特征曲线分析计算SII作为AE治疗反应外周生物标志物的预测价值,结果显示预测AE治疗反应不佳的最佳SII临界值为863.3;曲线下面积为0.75,敏感性为83.0%,特异性为72.0%。分析了AE治疗反应不佳的危险因素;单因素分析显示,30天后AE免疫治疗反应不佳的患者意识水平下降率、认知或精神行为异常率、脑脊液压力、血中性粒细胞、血小板、治疗开始时间、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及SII均显著高于反应良好的患者。同时,反应不佳患者的血淋巴细胞计数和格拉斯哥昏迷量表(GCS)评分显著低于反应良好的患者(均P<0.05),多因素二元logistic回归向后逐步法显示意识水平下降、治疗开始时间和SII与免疫治疗反应不佳有关。此外,SII≤863.3组意识水平下降率、入住重症监护病房率和机械通气率较低;脑脊液压力、血中性粒细胞计数和血小板计数较低;血淋巴细胞计数和GCS评分较高。SII与初诊AE 30天后疾病严重程度加重及治疗反应不佳有关,SII>863.3的患者更可能对免疫治疗反应不佳。